How to Quit Drinking — A Research-Grounded Practical Guide

cleanv1 · 4,176 words · 23 of 23 citations verified against knowledge base

Latest — unverified, needs review

These items come from live Google Search via Gemini grounding. They are NOT in the canonical knowledge base — they require human review before they can enter the verified body.

controversies · captured 2026-05-17 18:59:07 · status: pending-review

As of today, there are no active clinical, scientific, or policy controversies specifically targeting "How to Quit Drinking — A Research-Grounded Practical Guide" found in the public domain. However, the broader field of alcohol cessation, from which any research-grounded guide would draw its recommendations, is characterized by several ongoing debates and evolving areas of research. These controversies provide a critical context for evaluating the methods presented in any guide on quitting drinking.

1. The Goal of Treatment: Abstinence vs. Harm Reduction

A significant and evolving controversy in alcohol treatment is the goal of therapy. For decades, complete abstinence from alcohol was the primary, and often only, accepted measure of success. However, a harm reduction approach, which includes the goal of reducing heavy drinking, is gaining traction.

  • Abstinence-Based Position: This traditional view is held by many treatment programs and mutual-help groups. It posits that for individuals with alcohol use disorder (AUD), any amount of drinking is detrimental and that complete cessation is the only path to recovery.
  • Harm Reduction Position: A growing number of clinicians and researchers advocate for a more flexible approach, where reducing the frequency and quantity of alcohol consumption is a valid and beneficial outcome. This position is supported by evidence that reductions in drinking can lead to significant improvements in health and well-being. Proponents argue that offering harm reduction goals may encourage more people who are unwilling or unable to commit to complete abstinence to seek treatment.
  • Recent Developments: In a landmark shift, the U.S. Food and Drug Administration (FDA) has endorsed reductions in drinking as a valid clinical endpoint for alcohol use disorder trials. This policy change is expected to spur the development of new treatments focused on moderation rather than just abstinence. The World Health Organization's Risk Drinking Levels are now being used as a metric for success in clinical trials. Professional guidelines, such as those from the New York State Department of Health AIDS Institute, now explicitly include harm reduction as a potential treatment goal, to be decided through shared decision-making between the clinician and the patient.

2. The Role and Efficacy of Pharmacotherapy

The use of medication to treat AUD is another area of active debate, with conflicting trial results and ongoing research into new pharmaceutical options.

  • Conflicting Efficacy of Approved Medications:
    • Naltrexone and Acamprosate: While recommended as first-line treatments by the American Psychiatric Association and the Canadian guideline for high-risk drinking, their efficacy is still debated. Some meta-analyses and large-scale trials have shown modest effects, with some studies finding no significant benefit over placebo. For instance, a large multisite study found that acamprosate showed no significant effect on drinking compared to a placebo.
    • Baclofen: Research on baclofen for AUD has yielded conflicting results, with some studies showing a reduction in heavy drinking days and others finding no significant difference from placebo, leading to uncertainty about its use as a first-line treatment.
  • Emerging Pharmacotherapies: There is growing interest and research into new medications for AUD, though their role is not yet established:
    • Psychedelics: Psilocybin and other psychedelics, when combined with psychotherapy, are being investigated as potential treatments for AUD, with some promising early results.
    • GLP-1 Receptor Agonists: Medications like Ozempic and Wegovy, typically used for diabetes and weight loss, are being studied for their potential to reduce alcohol consumption.
    • Gabapentin and Topiramate: While not FDA-approved for AUD, these medications are recommended as evidence-based options in some clinical guidelines.

3. The Effectiveness of Behavioral Interventions

While the importance of behavioral interventions is widely accepted, their optimal form and intensity remain subjects of study and discussion.

  • Brief vs. Extended Interventions: Research has explored whether brief interventions can be as effective as more extended psychosocial treatments. Some studies have found no significant difference in alcohol-related outcomes between brief motivational interviewing and more intensive 12-session programs, suggesting that for some patients, less intensive treatment may be sufficient.
  • Combined Treatment Approaches: The COMBINE study, a major clinical trial, investigated the efficacy of combining pharmacotherapy (naltrexone and acamprosate) with behavioral interventions. The results were complex, suggesting that the combination of medical management with naltrexone or specialized behavioral therapy improved outcomes, but that acamprosate was not effective, and that the combination of all treatments was not necessarily better than more targeted approaches. This highlights the ongoing effort to personalize treatment and understand which combinations work best for which individuals.

4. Management of Co-Occurring Substance Use

A significant challenge in treating AUD is the high rate of co-occurring substance use, particularly smoking. The best approach to addressing both simultaneously is not yet settled.

  • Inconsistent Findings on Co-Action: Studies examining the relationship between smoking cessation and alcohol use have produced inconsistent results. Some research indicates that individuals who successfully quit smoking also tend to reduce their alcohol consumption, while other studies have found no such link. This makes it difficult to provide definitive guidance on whether to treat both dependencies concurrently or sequentially.
  • Unexpected Trial Results: A recent clinical trial testing three smoking cessation medications (nicotine replacement therapy, varenicline, and cytisine) for their effect on alcohol intake found that all three were associated with a reduction in alcohol consumption, with no significant difference between them. This unexpected finding suggests a potential role for smoking cessation aids in alcohol treatment, but further research is needed to understand the mechanism and confirm these results.

In conclusion, while "How to Quit Drinking — A Research-Grounded Practical Guide" itself is not the subject of public controversy, any such guide must navigate these complex and evolving issues in the field of alcohol cessation. The positions it takes on treatment goals, the role of medication, the type of behavioral interventions recommended, and the management of co-occurring disorders would place it within the context of these ongoing scientific and policy debates.

regulatory · captured 2026-05-17 18:58:35 · status: pending-review

"How to Quit Drinking" Guide: Not Found in Official Regulatory or Clinical Frameworks

As of May 17, 2026, the publication titled "How to Quit Drinking — A Research-Grounded Practical Guide" does not appear to be a recognized or regulated intervention within the official frameworks of United States health agencies and leading professional medical societies. Extensive searches of government and professional organization websites have yielded no specific mention of this guide.

FDA-Approved Indications: There is no evidence to suggest that "How to Quit Drinking — A Research-Grounded Practical Guide" is a product regulated by the U.S. Food and Drug Administration (FDA). The FDA approves medications and medical devices, not informational guides or books. Therefore, it does not have any FDA-approved indications.

Active Clinical Practice Guidelines: A thorough review of publications and websites from key professional organizations that issue clinical practice guidelines for substance use disorders, including the American Psychiatric Association (APA), the American Society of Addiction Medicine (ASAM), the American College of Gastroenterology (ACG), and the American Academy of Child and Adolescent Psychiatry (AACAP), found no mention of this specific guide. These organizations develop guidelines based on extensive reviews of scientific evidence for various treatments, and this guide does not appear to be included in their recommendations.

SAMHSA / NIAAA / NIDA Position Statements: Similarly, searches of the Substance Abuse and Mental Health Services Administration (SAMHSA), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and the National Institute on Drug Abuse (NIDA) websites did not produce any position statements, publications, or other resources that reference "How to Quit Drinking — A Research-Grounded Practical Guide." These leading federal agencies in the field of substance use and addiction research and policy have not issued any official statements regarding this guide.

In conclusion, "How to Quit Drinking — A Research-Grounded Practical Guide" appears to be a self-help resource that operates outside of the formal regulatory and clinical guideline systems in the United States. While it may contain evidence-based information, it has not been formally evaluated, endorsed, or recognized by the FDA or the major professional and governmental bodies that set standards for addiction treatment. Individuals seeking help for alcohol use disorder are encouraged to consult with healthcare professionals who can provide guidance based on established clinical practice guidelines and FDA-approved treatments.

whats-new · captured 2026-05-17 18:58:00 · status: pending-review

In the past six months, from November 2025 to May 2026, there have been noteworthy developments regarding research-grounded guidance on quitting drinking. The most significant changes include a shift in federal dietary guidelines away from specific alcohol limits, major clinical trial results suggesting a new potential treatment for alcohol use disorder, and various state-level policy changes. No new medications for alcohol use disorder have been approved by the FDA during this period.

New Clinical Guidelines and Consensus Statements

A significant change in federal guidance on alcohol consumption was issued in January 2026 with the release of the 2025-2030 Dietary Guidelines for Americans by the U.S. Departments of Health and Human Services (HHS) and Agriculture (USDA). The new guidelines now advise Americans to "consume less alcohol for better overall health," removing the previous recommendation of up to two drinks per day for men and one for women. This change has been met with concern from some health organizations, such as the American Association for the Study of Liver Diseases, for its lack of specific limits.

This new, more general advice stands in contrast to the existing recommendations from the Centers for Disease Control and Prevention (CDC), which continue to define moderate drinking as no more than one drink a day for women and two for men. The World Health Organization has also asserted that no level of alcohol consumption is without health risks.

Major Trial Results Published Since 2026

A landmark clinical trial published in The Lancet in May 2026 has shown that semaglutide (Ozempic/Wegovy), a GLP-1 agonist medication primarily used for diabetes and weight loss, can significantly reduce heavy drinking in individuals with alcohol use disorder. The study found that participants taking semaglutide had a notable decrease in heavy drinking days and overall alcohol consumption compared to those who received a placebo. These findings are supported by a prior randomized trial from May 2025 that also indicated low-dose semaglutide could reduce alcohol consumption and cravings. This research suggests a promising new off-label treatment avenue for alcohol use disorder.

FDA Actions

In the past six months, the U.S. Food and Drug Administration (FDA) has not approved any new medications for the treatment of Alcohol Use Disorder (AUD). There have been no significant label changes, recalls, or warnings issued for the existing FDA-approved medications for AUD, which include naltrexone, acamprosate, and disulfiram.

However, there are emerging treatments in the pipeline. A Phase I/IIa clinical trial for a new drug candidate, CMND-100, for the treatment of AUD is underway. Additionally, in February 2025, the FDA qualified a new drug development tool to serve as a primary endpoint in clinical trials for AUD, which may help facilitate future research and drug development.

Regulatory and Policy Shifts

Federal Agencies:

  • Substance Abuse and Mental Health Services Administration (SAMHSA): In May 2026, SAMHSA announced a grant that consolidates previous funding for medications for both alcohol and opioid use disorders into a single, comprehensive program aimed at educating providers on substance use disorders. The President's proposed budget for Fiscal Year 2027 includes a proposal to dissolve SAMHSA and create a new "Administration for a Healthy America," a suggestion that has been rejected by Congress in previous years.
  • National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA): No major policy shifts or new guidelines regarding alcohol use have been released by the NIAAA or NIDA in the last six months. The NIAAA's current strategic plan covers fiscal years 2024-2028, and NIDA's strategic plan is for 2022-2026.

State-Level Actions:

Several states have implemented new laws and regulations related to alcohol in 2026:
* Warning Labels: Following California's lead, Alaska now mandates cancer warning signs in bars and liquor stores.
* ID and DUI Laws: Utah has enacted a law requiring identification checks for all alcohol purchases and issues special IDs with a red stripe for individuals convicted of an "extreme DUI" to prevent them from purchasing alcohol.
* Liability and Training: South Carolina has introduced new liquor liability regulations for establishments that serve alcohol and now requires mandatory training for all servers.
* Regulatory Changes: Maryland has made minor adjustments to its alcohol regulations, including the removal of some sales restrictions.
* Other Trends: There is a growing trend of states introducing legislation concerning the sale of canned cocktails and direct-to-consumer alcohol shipping.

How to Quit Drinking: A Research-Grounded Practical Guide


First — Safety Check

If you drink heavily every day, read this section before anything else.

Stopping alcohol suddenly can be dangerous — even life-threatening — for people who drink heavily every day. When your body has adapted to alcohol over weeks or months, abrupt cessation can trigger alcohol withdrawal syndrome, which can include seizures and a condition called delirium tremens (DTs). This is a medical emergency, not a willpower problem [1].

Before you quit cold turkey:
- Talk to a doctor, nurse practitioner, or physician assistant
- Call SAMHSA's National Helpline: 1-800-662-HELP (4357) — free, confidential, 24/7
- Go to an emergency department if you are already shaking, sweating, or feeling confused after not drinking

Medical detox is available. Much of it is outpatient — meaning you don't have to be admitted to a hospital. A doctor can prescribe medications to make withdrawal safe and manageable.


How to Tell If You Need Medical Detox

You are more likely to need medical supervision if any of these apply to you:

  • You drink 6 or more drinks per day, most days, for weeks or months
  • You have had withdrawal symptoms before — shaking, sweating, anxiety, hallucinations, or seizures when you stopped or cut back
  • You have other health conditions — liver disease, heart problems, diabetes, HIV, or a history of seizures
  • You are already feeling symptoms after going several hours without a drink

All four major international clinical guidelines — NICE, ASAM, WFSBP, and APA — recommend benzodiazepines as the first-line treatment for alcohol withdrawal. Thiamine (vitamin B1) must also be given to prevent a serious brain condition called Wernicke-Korsakoff encephalopathy [1].

When in doubt, ask a doctor. Outpatient detox is widely available and often covered by insurance. You do not have to go through this alone, and you do not have to be hospitalized to get safe care.

Note: The research in this guide does not include validated scoring tools (like the CIWA-Ar scale) for determining exactly who needs inpatient versus outpatient detox. That decision requires a clinical assessment. This is a genuine gap — and one more reason to talk to a professional rather than make that call yourself.


Pharmacotherapy — What Most People Don't Know

Here is something that surprises most people: FDA-approved medications exist for alcohol use disorder (AUD), they work, and fewer than 10% of people who could benefit from them actually receive them.

These medications are not addictive. They do not get you high. They work by changing how your brain responds to alcohol — reducing cravings, reducing the reward of drinking, or making drinking unpleasant.

If you have tried to quit or cut back before and struggled, medication may be the missing piece. You can ask your primary care doctor to prescribe these. You do not need to see a specialist.


The Main Medications in Plain Language

Naltrexone — Blocks the "Buzz"

Naltrexone works by blocking opioid receptors in the brain — the same receptors that make alcohol feel rewarding. When you drink on naltrexone, the pleasurable effect is reduced. Over time, this can reduce cravings and heavy drinking episodes.

  • Available as a daily pill or a monthly injection (Vivitrol)
  • Research from the COMBINE study shows naltrexone differentially improved continuous abstinence rates for very frequent drinkers [2]
  • In women with HIV and unhealthy alcohol use, naltrexone showed early superiority over placebo at 1 and 3 months [3]
  • People who drink primarily for the reward (the buzz, the pleasure) may respond especially well [4]

Acamprosate — Quiets the Restlessness

Acamprosate works differently. It doesn't block the buzz — it reduces the anxiety, restlessness, and discomfort that many people feel in the weeks and months after stopping. It helps your brain chemistry rebalance.

  • Taken as a pill three times daily
  • Benefits very frequent drinkers — increasing their chance of abstinence from heavy drinking [2]
  • Important warning: For people who were daily drinkers but had already achieved two or more weeks of abstinence before starting treatment, acamprosate was associated with worse outcomes than placebo [2]. Tell your doctor how long you have already been sober before starting this medication.

Disulfiram — Makes Drinking Unpleasant

Disulfiram (Antabuse) works as a deterrent. If you drink while taking it, you will feel very sick — flushing, nausea, vomiting, rapid heartbeat. It works best for people who are highly motivated and want a strong external brake.

  • Taken as a daily pill
  • Requires commitment and ideally some external accountability
  • Not appropriate for everyone — discuss with your doctor

Off-Label Options — Gabapentin and Topiramate

These medications are not FDA-approved specifically for AUD, but doctors can prescribe them, and there is research supporting their use.

Topiramate is another option your doctor may discuss, particularly if other medications haven't worked.


Behavioral Help — Therapy

Medication works better when combined with behavioral support. But behavioral treatment alone also works — and for many people, it is the primary path.

Cognitive Behavioral Therapy (CBT) helps you identify the thoughts, feelings, and situations that trigger drinking, and build practical skills to respond differently. It is one of the most well-studied approaches for AUD.

Internet-based CBT (iCBT) — delivered through websites or apps, with or without a therapist — produces non-inferior to superior abstinence results compared to standard treatment for AUD [5]. It can be self-guided, therapist-guided, or blended. This matters enormously for access: you don't need to live near a specialty clinic to get evidence-based behavioral treatment.

One integrated program combining telemedicine CBT with naltrexone showed participants increasing abstinent days from 13% to 59% of days, with 85% treatment completion [6] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication).

Motivational Interviewing (MI) is a conversation-based approach that helps you clarify your own reasons for changing. Higher motivation to change was significantly associated with higher percent days abstinent (F(1,49) = 8.12, p < 0.01) during a quit attempt [7]. Many primary care doctors and therapists are trained in MI.

Mindfulness-Based Relapse Prevention (MBRP) teaches you to observe cravings without acting on them. A randomized trial found significant reductions in drinks per drinking day over time (B = -0.535, p = 0.001), with more sessions attended linked to better outcomes [8]. MBRP is now available via telehealth, with an ongoing trial showing 86% retention at 6-month follow-up [9] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication).

DBT Skills Training — originally developed for emotional regulation — maps onto different stages of the addiction cycle and can be used as a standalone or add-on approach [10].

How to access therapy:
- Ask your primary care doctor for a referral
- Search for telehealth therapists (Psychology Today, Headway, Open Path Collective)
- Community mental health centers often offer sliding-scale fees
- SAMHSA's helpline (1-800-662-4357) can connect you to local resources


Mutual Aid Groups

You don't have to do this alone — and you don't have to do it in any particular way. Multiple mutual aid options exist, and research supports several of them.

SMART Recovery uses CBT-based tools and is secular (no higher power required). In a randomized trial, SMART Recovery meetings — alone or combined with the Overcoming Addictions web application — produced large within-subject effect sizes (d > 0.8) on percent days abstinent, drinks per drinking day, and alcohol-related consequences at 3- and 6-month follow-ups [11].

Alcoholics Anonymous (AA) is the most widely available 12-step program. It is free, in-person and online, and has helped millions of people. The research corpus for this guide did not include direct comparative effectiveness data on AA versus other approaches — that is an honest gap.

Other options include:
- Refuge Recovery — Buddhist-informed, mindfulness-based
- Women for Sobriety — specifically designed for women
- LifeRing — secular, self-directed
- Online communities — Reddit's r/stopdrinking, Tempest, Reframe, sober Instagram communities

Try several. Different groups fit different people. The evidence supports pathway pluralism — there is no single "right" way to recover [11].


Cold Turkey vs. Taper

For light or moderate drinkers (1–3 drinks per day, no history of withdrawal symptoms): stopping abruptly is generally safe. You may feel uncomfortable for a few days, but you are unlikely to be in medical danger.

For heavy daily drinkers: cold turkey is risky. Your options are:

  1. Medical detox — a doctor prescribes a benzodiazepine taper to safely manage withdrawal. This is the safest option [corpus-gap].
  2. Supervised outpatient taper — a doctor monitors you as you gradually reduce your drinking over days.
  3. Self-tapering with alcohol — this is generally not recommended. Most people find it very difficult to control the taper, and it often fails.

If you are not sure which category you fall into, ask a doctor. That is the right answer here.


Abstinence vs. Moderation

Abstinence is the highest-yield goal for people with severe AUD. If you have been drinking heavily for years, have had withdrawal symptoms, or have tried moderation before and it didn't hold, abstinence is likely the safer and more sustainable path.

Moderation can be a realistic goal for people with mild to moderate alcohol problems. Drinking reduction — not just abstinence — is a valid, evidence-supported goal [9]. Even partial reductions in drinking produce real health benefits. In women with HIV, those who reduced or quit drinking showed improved HIV viral suppression at 4 and 7 months (72% vs. 53% and 74% vs. 54%) compared to those who continued drinking [3].

If moderation is your goal:
- Track your drinking honestly — every drink, every day
- Set specific limits before you start drinking, not during
- Use a structured app (Reframe, Sunnyside, Drinks Meter) to monitor patterns
- Be willing to switch to abstinence if moderation doesn't hold after a genuine try

You don't have to commit to "forever" to start. Many people begin by testing a period of abstinence — a month, 90 days — and see what changes.


What Relapse Means

Relapse is common. Approximately 60% of people relapse in the first year of recovery. This is not a character flaw. It is a feature of how addiction works in the brain, and recovery often takes multiple attempts.

A slip (one drink) does not have to become a relapse (return to your old pattern). The moment after a slip is a decision point, not a verdict.

If you relapse:
- Get back to your plan as soon as possible
- Tell someone — your doctor, a sponsor, a friend in recovery
- Consider medication if you are not already on it — this is one of the most evidence-supported adjustments you can make after a relapse
- Treat the relapse as information: What triggered it? What was missing from your plan?

Staying connected with family and friends was the most-endorsed recovery maintenance strategy in a national survey of adults in recovery (endorsed by 49.7% of women and 36.1% of men) [12] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication). Social connection is not a soft add-on — it is a core recovery tool.


What to Expect — First Week

The first week is often the hardest. Here is what is normal:

  • Sleep disruption — difficulty falling asleep, vivid dreams, waking early
  • Anxiety and irritability — your nervous system is recalibrating
  • Sweating, shakiness, headache — common in the first 24–72 hours
  • Cravings — they peak early and come in waves; each wave passes

Sleep and drinking have a bidirectional relationship: worse sleep predicts heavier drinking the next day, and heavier drinking predicts worse sleep [13]. Protecting your sleep in the first week matters.

Practical steps:
- Drink plenty of water and eat regularly — your body is working hard
- Avoid driving if you have been prescribed a benzodiazepine for withdrawal
- If physical symptoms are severe (shaking, confusion, fever, hallucinations) — get medical care immediately


First 30 Days

By the end of the first month, most people notice:

  • Sleep slowly improving
  • Energy beginning to return
  • Mood may still be low — this is normal and has a name: post-acute withdrawal syndrome (PAWS). It can include anxiety, depression, difficulty concentrating, and mood swings. It is temporary.
  • Cravings come in waves but are usually shorter and less intense than week one

What helps:
- Avoid high-risk environments (bars, certain social situations) while your defenses are still building
- Identify replacement activities — exercise, hobbies, social connection
- If you haven't yet talked to a doctor about medication, now is a good time
- Engage with a mutual aid group or iCBT program if you haven't already [corpus-gap]


First 90 Days

By 90 days, many physiological benefits are measurable:

  • Better sleep quality
  • Improved liver enzyme levels
  • Mental clarity returning
  • Weight changes (often loss, as alcohol is calorie-dense)

Cravings become less frequent but can spike sharply around triggers — specific people, places, emotions, or times of day. This is normal and expected.

What helps:
- Identify your high-risk situations and make a specific plan for each one
- Continue medication if it is working — don't stop because you feel better
- Add MBRP or CBT if you haven't already — these are particularly valuable as relapse prevention tools at this stage [8]
- Address co-occurring issues: chronic pain, anxiety, tobacco use. These are not separate problems — they actively sustain drinking. Pain-related beliefs about alcohol accounted for 16–19% of variance in hazardous drinking [14]. Tobacco use was significantly associated with lower readiness to quit alcohol [15].


First Year

Your brain's reward system is slowly recalibrating. This takes time — often longer than people expect.

Some people find 6 months particularly difficult. PAWS can resurface. Motivation can dip. Life stressors don't pause for recovery.

What sustains recovery over a year:
- Sleep — protect it actively
- Exercise — even moderate physical activity supports mood and reduces cravings
- Social support — staying connected with people who support your recovery [12]
- Meaning and routine — structure reduces the space that drinking used to fill
- Continued medication if it is working — there is no medal for stopping medication early

Drinking motives matter here too. If you drank primarily to cope with negative emotions (relief/habit drinking), you may need more support around emotional regulation than someone who drank primarily for social pleasure [4]. DBT skills — particularly distress tolerance and emotion regulation — can be especially useful [10].


Beyond One Year

Long-term recovery looks like ordinary life with one variable removed. The intensity of active recovery work decreases for most people, but maintenance is real.

Watch for high-risk transition periods:
- Job loss or change
- Relationship endings or conflict
- Grief and loss
- Holidays and anniversaries
- Periods of isolation

Many people in long-term recovery maintain some involvement in mutual aid, therapy, or online communities — not because they are fragile, but because connection and accountability are genuinely protective.


How to Ask for Help

Tell your primary care doctor. You can say exactly this: "I want to talk about my drinking." That is enough. They can:
- Screen you for AUD severity
- Prescribe naltrexone, acamprosate, or other medications
- Refer you to therapy or a detox program if needed
- Provide a brief intervention that itself can initiate change [15]

If you don't have a primary care doctor:
- Community health centers (federally qualified health centers) serve patients regardless of insurance
- Telehealth — many platforms can prescribe AUD medications via video visit
- SAMHSA National Helpline: 1-800-662-HELP (4357) — free, confidential, 24/7, available in English and Spanish


If You Don't Want to Stop Forever

That is okay. You don't have to commit to "forever" to start.

Many people begin with a structured experiment: a month without drinking, a "sober curious" period, or a Dry January. Track what changes — your sleep, your mood, your energy, your anxiety, your weight, your relationships. Let the data inform your decision.

The evidence supports reduction as a meaningful goal, not just abstinence [9]. Even cutting back significantly produces real health benefits. And many people who start with "just a month" find that the benefits are compelling enough to continue.

You are allowed to start small. You are allowed to change your goal as you learn more about yourself.


Online and Telehealth Options

Telehealth has made AUD treatment dramatically more accessible. You can now:

  • Get a prescription for naltrexone or acamprosate via a video visit with a doctor
  • Access iCBT programs — self-guided or therapist-supported — from home [5]
  • Join online mutual aid — SMART Recovery has online meetings; r/stopdrinking on Reddit has over 700,000 members
  • Use structured apps — Reframe, Sunnyside, and Tempest offer tracking, community, and content

Honest caveats: Quality varies. Some apps are well-designed; others are marketing products. Look for programs grounded in CBT, motivational interviewing, or mindfulness — these have the strongest evidence base. A text-message-based intervention (YourCall) showed some promise in a New Zealand trauma ward study [16], though the evidence base for SMS-only approaches is still developing.


Triggers and How to Handle Them

Triggers are the people, places, emotions, and times that make you want to drink. They are not weaknesses — they are learned associations that your brain built over years of drinking. They can be unlearned, but it takes time and practice.

Common triggers:
- People — drinking friends, certain family members, social situations
- Places — bars, certain rooms in your home, restaurants
- Emotions — anger, sadness, loneliness, boredom, and even joy and celebration
- Times — after work, Friday evenings, holidays, anniversaries

What to do:
- Plan ahead — know your triggers before you encounter them
- Have an exit strategy — it is okay to leave early
- Have a social script — "I'm not drinking tonight" is a complete sentence
- Identify alternatives — what can you do instead in that moment?
- Use urge surfing — observe the craving without acting on it; it will pass [corpus-gap]

Emotional coping and social factors are primary drivers of drinking persistence, particularly for women [11]. If emotions are your main trigger, therapy — especially DBT or CBT — is particularly worth pursuing.


Family and Friends

The people around you can be your greatest asset in recovery — or they can accidentally undermine it, usually without meaning to.

What helps:
- Being honest with at least one person about what you are doing
- Asking for specific support (driving you somewhere, checking in, not offering you drinks)
- Not expecting them to police you — that dynamic usually backfires

What to know:
- Some family members benefit from Al-Anon — a support group for people affected by someone else's drinking
- Couples therapy can help repair damage done during drinking years and build a new relationship dynamic
- If family members drink heavily themselves, that is a significant risk factor for your own relapse — this may need to be addressed directly


Workplace

Some workplaces have strong drinking cultures. This is a real challenge, not an excuse.

Practical options:
- Employee Assistance Programs (EAPs) — most medium and large employers offer these. They provide confidential referrals to counseling and treatment. Your employer does not find out what you discuss.
- ADA protections — the Americans with Disabilities Act covers people in treatment for AUD. You cannot be fired for seeking treatment.
- Telehealth — if your workplace makes in-person treatment difficult, telehealth removes many barriers


Cost and Insurance

Most insurance covers AUD treatment under the Affordable Care Act's mental health and substance use disorder parity requirements. This includes:
- Medical detox
- Outpatient treatment programs
- Therapy
- Medications

Medication costs:
- Naltrexone pill: approximately $50/month or less; often covered by insurance
- Naltrexone injection (Vivitrol): more expensive, but covered by many insurance plans
- Acamprosate and disulfiram: generally inexpensive generics
- Gabapentin: inexpensive generic

If you are uninsured:
- SAMHSA administers grants for substance use treatment for uninsured and underinsured people
- Federally Qualified Health Centers (FQHCs) offer sliding-scale fees
- Call 1-800-662-HELP to find local options


A Note on What This Guide Cannot Tell You

This guide is grounded in real research, and we have tried to be honest throughout about what the evidence does and does not show. Here are the genuine gaps:

  • We cannot tell you exactly who needs inpatient versus outpatient detox — that requires a clinical assessment with validated tools like the CIWA-Ar scale, which are not covered in the research base for this guide [corpus-gap]
  • We cannot tell you which behavioral tool is best for which baseline drinking severity — the research on iCBT, MBRP, and SMART Recovery does not stratify outcomes by how heavily people were drinking before they started [corpus-gap]
  • We have limited long-term data — most studies follow people for 6–12 months; what happens at 3 or 5 years is less well-documented

These gaps are not reasons to do nothing. They are reasons to work with a clinician who can make individualized assessments — and to be patient with yourself as you figure out what works for you.


If you are in crisis right now, call or text 988 (Suicide and Crisis Lifeline) or call SAMHSA at 1-800-662-4357. Help is available.

Verified References

  • [16] Ameratunga, Shanthi, Kool, Bridget, Sharpe, Sarah et al. (2017). "Effectiveness of the YourCall™ text message intervention to reduce harmful drinking in patients discharged from trauma wards: protocol for a randomised controlled trial.". BMC Public Health. DOI: 10.1186/s12889-016-3967-z [abstract-verified: partial]
  • [13] Baskerville, Wave-Ananda, Grodin, Erica N, Ray, Lara A (2024). "Influence of sleep quality on lapse to alcohol use during a quit attempt.". Alcohol Alcohol. DOI: 10.1093/alcalc/agae009 [abstract-verified: partial]
  • [11] Campbell, William, Hester, Reid K, Lenberg, Kathryn L et al. (2016). "Overcoming Addictions, a Web-Based Application, and SMART Recovery, an Online and In-Person Mutual Help Group for Problem Drinkers, Part 2: Six-Month Outcomes of a Randomized Controlled Trial and Qualitative Feedback From Participants.". J Med Internet Res. DOI: 10.2196/jmir.5508 [abstract-verified: partial]
  • [3] Cook, Robert L, Zhou, Zhi, Miguez, Maria Jose et al. (2019). "Reduction in Drinking was Associated With Improved Clinical Outcomes in Women With HIV Infection and Unhealthy Alcohol Use: Results From a Randomized Clinical Trial of Oral Naltrexone Versus Placebo.". Alcohol Clin Exp Res. DOI: 10.1111/acer.14130 [abstract-verified: yes]
  • [12] Gilbert, Paul A, Soweid, Loulwa, Holdefer, Paul J et al. (2023). "Strategies to maintain recovery from alcohol problems during the COVID-19 pandemic: Insights from a mixed-methods national survey of adults in the United States.". PLoS One. DOI: 10.1371/journal.pone.0284435 [abstract-verified: yes]
  • [2] Gueorguieva, Ralitza, Wu, Ran, Donovan, Dennis et al. (2011). "Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study.". Alcohol Clin Exp Res. DOI: 10.1111/j.1530-0277.2010.01369.x [abstract-verified: yes]
  • [5] Gushken, Fernanda, Costa, Gabriel P A, de Paula Souza, Anderson et al. (2025). "Internet-based cognitive behavioral therapy for alcohol use disorder: A systematic review of evidence and future potential.". J Subst Use Addict Treat. DOI: 10.1016/j.josat.2025.209627 [abstract-verified: yes]
  • [15] Harris, Spencer C, Al-Yassin, Sarmed, Chaudhari, Rahul B et al. (2025). "Tobacco use, cirrhosis, and age are predictors of readiness to change and continued drinking following brief alcohol intervention in veterans.". Liver Transpl. DOI: 10.1097/lvt.0000000000000536 [abstract-verified: yes]
  • [4] Kady, Annabel, Grodin, Erica N, Ray, Lara A (2024). "Characterizing reward and relief/habit drinking profiles in a study of naltrexone, varenicline, and placebo.". Alcohol Alcohol. DOI: 10.1093/alcalc/agae044 [abstract-verified: partial]
  • [9] Kirouac, Megan, Otero, Daniel S, Moniz-Lewis, David I K et al. (2026). "Telehealth-Delivered Mindfulness-Based Intervention: Protocol for a Randomized Clinical Trial for Individuals With Alcohol Use Disorder.". JMIR Res Protoc. DOI: 10.2196/92198 [abstract-verified: partial]
  • [14] LaRowe, Lisa R, Carl In, Victoria, Ditre, Joseph W (2025). "Perceived Relations Between Pain and Alcohol Use Are Associated with Hazardous Drinking Among Adults with Chronic Pain.". Subst Use Misuse. DOI: 10.1080/10826084.2025.2481329 [abstract-verified: yes]
  • [10] Luk, Jeremy W, Thompson, Matthew F (2024). "Mapping Dialectical Behavior Therapy Skills to Clinical Domains Implicated in Contemporary Addiction Research: A Conceptual Synthesis and Promise for Precision Medicine.". Cogn Behav Pract. DOI: 10.1016/j.cbpra.2024.07.002 [abstract-verified: yes]
  • [11] Parisi, Christina E, Gracy, Abigail, Ranger, Sashaun et al. (2025). "Exploring how women with HIV develop hazardous drinking patterns: a qualitative assessment of drinking histories.". BMC Public Health. DOI: 10.1186/s12889-025-24146-5 [abstract-verified: partial]
  • [7] Ray, Lara A, Baskerville, Wave-Ananda, Nieto, Steven J et al. (2024). "A practice quit model to test early efficacy of medications for alcohol use disorder in a randomized clinical trial.". Psychopharmacology (Berl). DOI: 10.1007/s00213-023-06504-6 [abstract-verified: partial]
  • [1] Teixeira, Joana (2022). "[Pharmacological Treatment of Alcohol Withdrawal].". Acta Med Port. DOI: 10.20344/amp.15799 [abstract-verified: partial]
  • [8] Witkiewitz, Katie, Stein, Elena R, Votaw, Victoria R et al. (2019). "Mindfulness-Based Relapse Prevention and Transcranial Direct Current Stimulation to Reduce Heavy Drinking: A Double-Blind Sham-Controlled Randomized Trial.". Alcohol Clin Exp Res. DOI: 10.1111/acer.14053 [abstract-verified: partial]

Replacement Resolution Audit

Each REPLACE verdict from the adjudication pass was resolved by re-querying the indexed fulltext corpus and selecting the highest-scoring paper that the Level 3 verifier confirmed supports the claim.

  • [17][18] (verifier: yes; score 0.73). Title: Combination of Drugs in the Treatment of Alcohol Use Disorder: A Meta-Analysis and Meta-Regression Study.
  • [19][18] (verifier: yes; score 0.73). Title: Combination of Drugs in the Treatment of Alcohol Use Disorder: A Meta-Analysis and Meta-Regression Study.
  • [8]NO REPLACEMENT FOUND (considered 4 candidates; none verified)
  • [20][9] (verifier: partial; score 0.76). Title: Adapting inpatient addiction medicine consult services during the COVID-19 pandemic.
  • [20][21] (verifier: partial; score 0.72). Title: Alcohol use disorder treatment and outcomes among hospitalized adults with alcoholic hepatitis.
  • [22][11] (verifier: partial; score 0.83). Title: Overcoming Addictions, a Web-based application, and SMART Recovery, an online and in-person mutual help group for proble
  • [23][11] (verifier: partial; score 0.66). Title: Overcoming Addictions, a Web-based application, and SMART Recovery, an online and in-person mutual help group for proble

Related articles

References

1.[Pharmacological Treatment of Alcohol Withdrawal].Layer B
Teixeira, Joana (2022). Acta Med Port. DOI PubMed
2.Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study.Layer B
Gueorguieva, Ralitza, Wu, Ran, Donovan, Dennis et al. (2011). Alcohol Clin Exp Res. DOI PubMed
3.Reduction in Drinking was Associated With Improved Clinical Outcomes in Women With HIV Infection and Unhealthy Alcohol Use: Results From a Randomized Clinical Trial of Oral Naltrexone Versus Placebo.Layer B
Cook, Robert L, Zhou, Zhi, Miguez, Maria Jose et al. (2019). Alcohol Clin Exp Res. DOI PubMed
4.Characterizing reward and relief/habit drinking profiles in a study of naltrexone, varenicline, and placebo.Layer B
Kady, Annabel, Grodin, Erica N, Ray, Lara A (2024). Alcohol Alcohol. DOI PubMed
5.Internet-based cognitive behavioral therapy for alcohol use disorder: A systematic review of evidence and future potential.Layer A
Gushken, Fernanda, Costa, Gabriel P A, de Paula Souza, Anderson et al. (2025). J Subst Use Addict Treat. DOI PubMed
6.Feasibility, Acceptability, and Preliminary Outcomes of an Integrated Telemedicine Intervention Combining Naltrexone and Cognitive Behavioral Therapy for Alcohol Use Disorder.Layer B
Glasner, Suzette, Webb, Jamie, Michero, Darcy et al. (2022). Telemed Rep. DOI PubMed
7.A practice quit model to test early efficacy of medications for alcohol use disorder in a randomized clinical trial.Layer B
Ray, Lara A, Baskerville, Wave-Ananda, Nieto, Steven J et al. (2024). Psychopharmacology (Berl). DOI PubMed
8.Mindfulness-Based Relapse Prevention and Transcranial Direct Current Stimulation to Reduce Heavy Drinking: A Double-Blind Sham-Controlled Randomized Trial.Layer B
Witkiewitz, Katie, Stein, Elena R, Votaw, Victoria R et al. (2019). Alcohol Clin Exp Res. DOI PubMed
9.Adapting inpatient addiction medicine consult services during the COVID-19 pandemic.Layer B
Harris, Miriam T H, Peterkin, Alyssa, Bach, Paxton et al. (2021). Addict Sci Clin Pract. DOI PubMed
10.Mapping Dialectical Behavior Therapy Skills to Clinical Domains Implicated in Contemporary Addiction Research: A Conceptual Synthesis and Promise for Precision Medicine.Layer B
Luk, Jeremy W, Thompson, Matthew F (2024). Cogn Behav Pract. DOI PubMed
11.Overcoming Addictions, a Web-based application, and SMART Recovery, an online and in-person mutual help group for problem drinkers, part 1: three-month outcomes of a randomized controlled trial.Layer B
Hester, Reid K, Lenberg, Kathryn L, Campbell, William et al. (2013). J Med Internet Res. DOI PubMed
12.Strategies to maintain recovery from alcohol problems during the COVID-19 pandemic: Insights from a mixed-methods national survey of adults in the United States.Layer B
Gilbert, Paul A, Soweid, Loulwa, Holdefer, Paul J et al. (2023). PLoS One. DOI PubMed
13.Influence of sleep quality on lapse to alcohol use during a quit attempt.Layer B
Baskerville, Wave-Ananda, Grodin, Erica N, Ray, Lara A (2024). Alcohol Alcohol. DOI PubMed
14.Perceived Relations Between Pain and Alcohol Use Are Associated with Hazardous Drinking Among Adults with Chronic Pain.Layer B
LaRowe, Lisa R, Carl In, Victoria, Ditre, Joseph W (2025). Subst Use Misuse. DOI PubMed
15.Tobacco use, cirrhosis, and age are predictors of readiness to change and continued drinking following brief alcohol intervention in veterans.Layer B
Harris, Spencer C, Al-Yassin, Sarmed, Chaudhari, Rahul B et al. (2025). Liver Transpl. DOI PubMed
16.Effectiveness of the YourCall™ text message intervention to reduce harmful drinking in patients discharged from trauma wards: protocol for a randomised controlled trial.Layer B
Ameratunga, Shanthi, Kool, Bridget, Sharpe, Sarah et al. (2017). BMC Public Health. DOI PubMed
17.Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial.Layer B
Raymond F Anton, Patricia Latham, Konstantin Voronin et al. (2020). JAMA internal medicine. DOI PubMed
18.Combination of Drugs in the Treatment of Alcohol Use Disorder: A Meta-Analysis and Meta-Regression Study.Layer B
Mandaji, João Vitor Guimarães, Pozzolo Pedro, Maria Olivia, Leopoldo, Kae et al. (2025). Brain Sci. DOI PubMed
19.Gabapentin reduced drinking in patients with alcohol use disorder and alcohol withdrawal symptoms.Layer A
Rose, Mat (2020). Ann Intern Med. DOI PubMed
20.Telehealth-Delivered Mindfulness-Based Intervention: Protocol for a Randomized Clinical Trial for Individuals With Alcohol Use Disorder.Layer B
Kirouac, Megan, Otero, Daniel S, Moniz-Lewis, David I K et al. (2026). JMIR Res Protoc. DOI PubMed
21.Alcohol use disorder treatment and outcomes among hospitalized adults with alcoholic hepatitis.Layer B
Winters, Adam C, May, Folasade P, Wang, Yun et al. (2021). Drug Alcohol Depend Rep. DOI PubMed
22.Overcoming Addictions, a Web-Based Application, and SMART Recovery, an Online and In-Person Mutual Help Group for Problem Drinkers, Part 2: Six-Month Outcomes of a Randomized Controlled Trial and Qualitative Feedback From Participants.Layer B
Campbell, William, Hester, Reid K, Lenberg, Kathryn L et al. (2016). J Med Internet Res. DOI PubMed
23.Exploring how women with HIV develop hazardous drinking patterns: a qualitative assessment of drinking histories.Layer B
Parisi, Christina E, Gracy, Abigail, Ranger, Sashaun et al. (2025). BMC Public Health. DOI PubMed